Interplay of breast cancer resistance protein (BCRP) and metabolizing enzy

Current Drug Metabolism

Volumn 16, Issue 10, 2015, Pages 877-893

  Tian, Ye ^a,b,c   Bian, Yicong ^a   Jiang, Yan ^a   Qian, Sainan ^a   Yu, Aiming ^c   Zeng, Su ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BCRP; Elimination; Interplay; Organs; Phase I metabolizing enzymes; Phase II metabolizing enzymes

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450; FLAVONOID; STEROID HORMONE; WATER; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; DRUG; ENZYME; TUMOR PROTEIN; XENOBIOTIC AGENT;

ARTICLE; BIOTRANSFORMATION; BLOOD BRAIN BARRIER; BRAIN; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; KIDNEY; LIVER; LUNG; NONHUMAN; PLACENTA; PROTEIN ANALYSIS; ANIMAL; CELL MEMBRANE; CHEMISTRY; METABOLISM; MOLECULAR WEIGHT; SOLUBILITY;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CELL MEMBRANE; ENZYMES; HUMANS; MOLECULAR WEIGHT; NEOPLASM PROTEINS; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; XENOBIOTICS;

EID: 84959283893     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920021610151210184205     Document Type: Article

References (151)

1. Zamek-Gliszczynski, M. J.; Hoffmaster, K. A.; Nezasa, K.; Tallman, M. N.; Brouwer, K. L. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur. J. Pharm. Sci., 2006, 27 (5), 447-86.
2. Schlichting, I.; Berendzen, J.; Chu, K.; Stock, A. M.; Maves, S. A.; Benson, D. E.; Sweet, R. M.; Ringe, D.; Petsko, G. A.; Sligar, S. G. The catalytic pathway of cytochrome p450cam at atomic resolution. Science, 2000, 287 (5458), 1615-22.
3. Guengerich, F. P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol, 2001, 14 (6), 611-50.
4. Jakoby, W. B.; Ziegler, D. M. The enzymes of detoxication. J. Biol. Chem., 1990, 265 (34), 20715-8.
5. Nishiyama, T.; Kobori, T.; Arai, K.; Ogura, K.; Ohnuma, T.; Ishii, K.; Hayashi, K.; Hiratsuka, A. Identification of human UDP-glucuronosyltransferase isoform(s) responsible for the C-glucuronidation of phenylbutazone. Arch. Biochem. Biophys., 2006, 454 (1), 72-9.
6. Tukey, R. H.; Strassburg, C. P. Human UDP-glucuronosyl-transferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol, 2000, 40, 581-616.
7. Chiu, S. H.; Huskey, S. W. Species differences in N-glucuronidation. Drug Metab. Dispos., 1998, 26 (9), 838-47.
8. Baker, C. A.; Uno, H.; Johnson, G. A. Minoxidil sulfation in the hair follicle. Skin Pharmacol, 1994, 7 (6), 335-9.
9. Kurogi, K.; Chen, M.; Lee, Y.; Shi, B.; Yan, T.; Liu, M. Y.; Sakakibara, Y.; Suiko, M.; Liu, M. C. Sulfation of buprenorphine, pentazocine, and naloxone by human cytosolic sulfotransferases. Drug Metab. Lett., 2012, 6 (2), 109-15.
10. Edavana, V. K.; Yu, X.; Dhakal, I. B.; Williams, S.; Ning, B.; Cook, I. T.; Caldwell, D.; Falany, C. N.; Kadlubar, S. Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1. Pharmgenomics Pers. Med, 2011, 4, 137-145.
11. Foureman, G. L.; Hernandez, O.; Bhatia, A.; Bend, J. R. The stereoselectivity of four hepatic glutathione S-transferases purified from a marine elasmobranch (Raja erinacea) with several K-region polycyclic arene oxide substrates. Biochim. Biophys. Acta, 1987, 914 (2), 127-35.
12. Anders, M. W. Glutathione-dependent bioactivation of haloalkanes and haloalkenes. Drug Metab. Rev., 2004, 36 (3-4), 583-94.
13. Wang, C; Liu, K. X. The drug-drug interaction mediated by efflux transporters and CYP450 enzymes. Yao Xue Xue Bao, 2014, 49 (5), 590-5.
14. Jeong, E. J.; Liu, X.; Jia, X.; Chen, J.; Hu, M. Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions. Curr. Drug Metab., 2005, 6 (5), 455-68.
15. Englund, G.; Lundquist, P.; Skogastierna, C; Johansson, J.; Hoogstraate, J.; Afzelius, L.; Andersson, T. B.; Projean, D. Cytochrome p450 inhibitory properties of common efflux transporter inhibitors. Drug Metab. Dispos., 2014, 42 (3), 441-7.
16. Kostrubsky, V. E.; Vore, M.; Kindt, E.; Burliegh, J.; Rogers, K.; Peter, G.; Altrogge, D.; Sinz, M. W. The effect of troglitazone biliary excretion on metabolite distribution and cholestasis in transporter-deficient rats. Drug Metab. Dispos., 2001, 29 (12), 1561-6.
17. Cummins, C. L.; Jacobsen, W.; Benet, L. Z. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther., 2002, 300 (3), 1036-45.
18. Cummins, C. L.; Jacobsen, W.; Christians, U.; Benet, L. Z. CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J. Pharmacol. Exp. Ther., 2004, 308 (1), 143-55.
19. Benet, L. Z. The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol. Pharm., 2009, 6 (6), 1631-43.
20. Benet, L. Z.; Cummins, C. L.; Wu, C. Y. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int. J. Pharm., 2004, 277 (1-2), 3-9.
21. Decleves, X.; Jacob, A.; Yousif, S.; Shawahna, R.; Potin, S.; Scherrmann, J. M. Interplay of drug metabolizing CYP450 enzymes and ABC transporters in the blood-brain barrier. Curr. Drug Metab., 2011, 12 (8), 732-41.
22. Krishnamurthy, P.; Schuetz, J. D. Role of ABCG2/BCRP in biology and medicine. Annu. Rev. Pharmacol. Toxicol., 2006, 46, 381-410.
23. Mao, Q.; Unadkat, J. D. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J., 2005, 7 (1), E118-33.
24. Allen, J. D.; Schinkel, A. H. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol. Cancer Ther., 2002, 1 (6), 427-34.
25. Han, B.; Zhang, J. T. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2. Curr. Med. Chem. Anticancer Agents, 2004, 4 (1), 31-42.
26. Ishikawa, T.; Nakagawa, H. Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics. J. Exp. Ther. Oncol., 2009, 8 (1), 5-24.
27. Rabindran, S. K.; Ross, D. D.; Doyle, L. A.; Yang, W.; Greenberger, L. M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res., 2000, 60 (1), 47-50.
28. Zhang, S.; Wang, X.; Sagawa, K.; Morris, M. E. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice. Drug Metab. Dispos., 2005, 33 (3), 341-8.
29. Jiang, W.; Xu, B.; Wu, B.; Yu, R.; Hu, M. UDP-glucuronosyl-transferase (UGT) 1A9-overexpressing HeLa cells is an appropriate tool to delineate the kinetic interplay between breast cancer resistance protein (BRCP) and UGT and to rapidly identify the glucuronide substrates of BCRP. Drug Metab. Dispos., 2012, 40 (2), 336-45.
30. Alfaras, I.; Perez, M.; Juan, M. E.; Merino, G.; Prieto, J. G.; Planas, J. M.; Alvarez, A. I. Involvement of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue distribution of trans-resveratrol in knockout mice. J. Agric. Food Chem., 2010, 58 (7), 4523-8.
31. Zamek-Gliszczynski, M. J.; Nezasa, K.; Tian, X.; Kalvass, J. C.; Patel, N. J.; Raub, T. J.; Brouwer, K. L. The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Mol. Pharmacol., 2006, 70 (6), 2127-33.
32. Suzuki, M.; Suzuki, H.; Sugimoto, Y.; Sugiyama, Y. ABCG2 transports sulfated conjugates of steroids and xenobiotics. J. Biol. Chem., 2003, 278 (25), 22644-9.
33. Doyle, L. A.; Yang, W.; Abruzzo, L. V.; Krogmann, T.; Gao, Y.; Rishi, A. K.; Ross, D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U S A, 1998, 95 (26), 15665-70.
34. Maliepaard, M.; Scheffer, G. L.; Faneyte, I. F.; van Gastelen, M. A.; Pijnenborg, A. C.; Schinkel, A. H.; van De Vijver, M. J.; Scheper, R. J.; Schellens, J. H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res., 2001, 61 (8), 3458-64.
35. Hirano, M.; Maeda, K.; Matsushima, S.; Nozaki, Y.; Kusuhara, H.; Sugiyama, Y. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol. Pharmacol., 2005, 68 (3), 800-7.
36. Scalbert, A.; Williamson, G. Dietary intake and bioavailability of polyphenols. J. Nutr., 2000, 130 (8S Suppl), 2073S-85S.
37. Law, M. R.; Morris, J. K. By how much does fruit and vegetable consumption reduce the risk of ischaemic heart disease? Eur. J. Clin. Nutr., 1998, 52 (8), 549-56.
38. Sesink, A. L.; Arts, I. C.; de Boer, V. C.; Breedveld, P.; Schellens, J. H.; Hollman, P. C.; Russel, F. G. Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. Mol. Pharmacol., 2005, 67 (6), 1999-2006.
39. Yang, Z.; Zhu, W.; Gao, S.; Yin, T.; Jiang, W.; Hu, M. Breast cancer resistance protein (ABCG2) determines distribution of ge-nistein phase II metabolites: reevaluation of the roles of ABCG2 in the disposition of genistein. Drug Metab. Dispos., 2012, 40 (10), 1883-93.
40. Funk, C.; Ponelle, C.; Scheuermann, G.; Pantze, M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol., 2001, 59 (3), 627-35.
41. Zelcer, N.; van de Wetering, K.; Hillebrand, M.; Sarton, E.; Kuil, A.; Wielinga, P. R.; Tephly, T.; Dahan, A.; Beijnen, J. H.; Borst, P. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc. Natl. Acad. Sci.U S A, 2005, 102 (20), 7274-9.
42. Zamek-Gliszczynski, M. J.; Hoffmaster, K. A.; Nezasa, K.; Brouwer, K. L. Apparent differences in mechanisms of harmol sulfate biliary excretion in mice and rats. Drug Metab. Dispos., 2008, 36 (11), 2156-8.
43. Chen, C. Troglitazone: an antidiabetic agent. Am. J. Health Syst. Pharm., 1998, 55 (9), 905-25.
44. Enokizono, J.; Kusuhara, H.; Sugiyama, Y. Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect. Drug Metab. Dispos., 2007, 35 (2), 209-14.
45. Honma, W.; Shimada, M.; Sasano, H.; Ozawa, S.; Miyata, M.; Nagata, K.; Ikeda, T.; Yamazoe, Y. Phenol sulfotransferase, ST1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver. Drug Metab. Dispos., 2002, 30 (8), 944-9.
46. Park, B. K.; Kitteringham, N. R.; Maggs, J. L.; Pirmohamed, M.; Williams, D. P. The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 177-202.
47. Zamek-Gliszczynski, M. J.; Hoffmaster, K. A.; Tian, X.; Zhao, R.; Polli, J. W.; Humphreys, J. E.; Webster, L. O.; Bridges, A. S.; Kalvass, J. C.; Brouwer, K. L. Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1. Drug Metab. Dispos., 2005, 33 (8), 1158-65.
48. Lee, J. K.; Abe, K.; Bridges, A. S.; Patel, N. J.; Raub, T. J.; Pollack, G. M.; Brouwer, K. L. Sex-dependent disposition of acetaminophen sulfate and glucuronide in the in situ perfused mouse liver. Drug Metab. Dispos., 2009, 37 (9), 1916-21.
49. Breedveld, P.; Pluim, D.; Cipriani, G.; Dahlhaus, F.; van Eijndhoven, M. A.; de Wolf, C. J.; Kuil, A.; Beijnen, J. H.; Scheffer, G. L.; Jansen, G.; Borst, P.; Schellens, J. H. The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol. Pharmacol., 2007, 71 (1), 240-9.
50. Jordan, C. G.; Rashidi, M. R.; Laljee, H.; Clarke, S. E.; Brown, J. E.; Beedham, C. Aldehyde oxidase-catalysed oxidation of methotrexate in the liver of guinea-pig, rabbit and man. J. Pharm. Pharmacol., 1999, 51 (4), 411-8.
51. Moriyasu, A.; Sugihara, K.; Nakatani, K.; Ohta, S.; Kitamura, S. In vivo-in vitro relationship of methotrexate 7-hydroxylation by aldehyde oxidase in four different strain rats. Drug Metab. Pharmacokinet., 2006, 21 (6), 485-91.
52. Vlaming, M. L.; Pala, Z.; van Esch, A.; Wagenaar, E.; de Waart, D. R.; van de Wetering, K.; van der Kruijssen, C. M.; Oude Elferink, R. P.; van Tellingen, O.; Schinkel, A. H. Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Clin. Cancer Res., 2009, 15 (9), 3084-93.
53. Enokizono, J.; Kusuhara, H.; Sugiyama, Y. Regional expression and activity of breast cancer resistance protein (Bcrp/Abcg2) in mouse intestine: overlapping distribution with sulfotransferases. Drug Metab. Dispos., 2007, 35 (6), 922-8.
54. Kaminsky, L. S.; Zhang, Q. Y. The small intestine as a xenobioticmetabolizing organ. Drug Metab. Dispos., 2003, 31 (12), 1520-5.
55. Chan, L. M.; Lowes, S.; Hirst, B. H. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci., 2004, 21 (1), 25-51.
56. Grams, B.; Harms, A.; Braun, S.; Strassburg, C. P.; Manns, M. P.; Obermayer-Straub, P. Distribution and inducibility by 3-methylcholanthrene of family 1 UDP-glucuronosyltransferases in the rat gastrointestinal tract. Arch. Biochem. Biophys., 2000, 377 (2), 255-65.
57. Liu, Z.; Hu, M. Natural polyphenol disposition via coupled metabolic pathways. Expert Opin. Drug Metab. Toxicol., 2007, 3 (3), 389-406.
58. Lamartiniere, C. A.; Cotroneo, M. S.; Fritz, W. A.; Wang, J.; Mentor-Marcel, R.; Elgavish, A. Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. J. Nutr., 2002, 132 (3), 552S-558S.
59. Setchell, K. D.; Brown, N. M.; Desai, P.; Zimmer-Nechemias, L.; Wolfe, B. E.; Brashear, W. T.; Kirschner, A. S.; Cassidy, A.; Heubi, J. E. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J. Nutr., 2001, 131 (4 Suppl), 1362S-75S.
60. Busby, M. G.; Jeffcoat, A. R.; Bloedon, L. T.; Koch, M. A.; Black, T.; Dix, K. J.; Heizer, W. D.; Thomas, B. F.; Hill, J. M.; Crowell, J. A.; Zeisel, S. H. Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am. J. Clin. Nutr., 2002, 75 (1), 126-36.
61. Zhu, W.; Xu, H.; Wang, S. W.; Hu, M. Breast cancer resistance protein (BCRP) and sulfotransferases contribute significantly to the disposition of genistein in mouse intestine. AAPS J., 2010, 12 (4), 525-36.
62. Alvarez, A. I.; Vallejo, F.; Barrera, B.; Merino, G.; Prieto, J. G.; Tomas-Barberan, F.; Espin, J. C. Bioavailability of the glucuronide and sulfate conjugates of genistein and daidzein in breast cancer resistance protein 1 knockout mice. Drug Metab. Dispos., 2011, 39 (11), 2008-12.
63. Coughtrie, M. W.; Sharp, S.; Maxwell, K.; Innes, N. P. Biology and function of the reversible sulfation pathway catalysed by human sulfotransferases and sulfatases. Chem. Biol. Interact., 1998, 109 (1-3), 3-27.
64. Buhl, A. E.; Waldon, D. J.; Baker, C. A.; Johnson, G. A. Minoxidil sulfate is the active metabolite that stimulates hair follicles. J. Invest. Dermatol., 1990, 95 (5), 553-7.
65. Kazerouni, N.; Sinha, R.; Hsu, C. H.; Greenberg, A.; Rothman, N. Analysis of 200 food items for benzo[a]pyrene and estimation of its intake in an epidemiologic study. Food Chem. Toxicol., 2001, 39 (5), 423-36.
66. Ebert, B.; Seidel, A.; Lampen, A. Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis, 2005, 26 (10), 1754-63.
67. Ebert, B.; Seidel, A.; Lampen, A. Phytochemicals induce breast cancer resistance protein in Caco-2 cells and enhance the transport of benzo[a]pyrene-3-sulfate. Toxicol. Sci., 2007, 96 (2), 227-36.
68. Hessel, S.; Lampen, A. All-trans retinoic acid enhances the transport of phase II metabolites of benzo[a]pyrene by inducing the Breast Cancer Resistance Protein expression in Caco-2 cells. Toxicol. Lett., 2010, 197 (2), 151-5.
69. Jonker, J. W.; Buitelaar, M.; Wagenaar, E.; Van Der Valk, M. A.; Scheffer, G. L.; Scheper, R. J.; Plosch, T.; Kuipers, F.; Elferink, R. P.; Rosing, H.; Beijnen, J. H.; Schinkel, A. H. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. U S A, 2002, 99 (24), 15649-54.
70. Nakamura, A.; Nakajima, M.; Yamanaka, H.; Fujiwara, R.; Yokoi, T. Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab. Dispos., 2008, 36 (8), 1461-4.
71. Lash, L. H.; Putt, D. A.; Cai, H. Drug metabolism enzyme expression and activity in primary cultures of human proximal tubular cells. Toxicology, 2008, 244 (1), 56-65.
72. Mizuno, N.; Takahashi, T.; Kusuhara, H.; Schuetz, J. D.; Niwa, T.; Sugiyama, Y. Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one). Drug Metab. Dispos., 2007, 35 (11), 2045-52.
73. Mizuno, N.; Suzuki, M.; Kusuhara, H.; Suzuki, H.; Takeuchi, K.; Niwa, T.; Jonker, J. W.; Sugiyama, Y. Impaired renal excretion of 6-hydroxy-5, 7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. Drug Metab. Dispos., 2004, 32 (9), 898-901.
74. Allen, J. D.; Brinkhuis, R. F.; Wijnholds, J.; Schinkel, A. H. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res., 1999, 59 (17), 4237-41.
75. Kawabata, S.; Oka, M.; Soda, H.; Shiozawa, K.; Nakatomi, K.; Tsurutani, J.; Nakamura, Y.; Doi, S.; Kitazaki, T.; Sugahara, K.; Yamada, Y.; Kamihira, S.; Kohno, S. Expression and functional analyses of breast cancer resistance protein in lung cancer. Clin. Cancer Res., 2003, 9 (8), 3052-7.
76. Doyle, L.; Ross, D. D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene, 2003, 22 (47), 7340-58.
77. Scheffer, G. L.; Pijnenborg, A. C.; Smit, E. F.; Muller, M.; Postma, D. S.; Timens, W.; van der Valk, P.; de Vries, E. G.; Scheper, R. J. Multidrug resistance related molecules in human and murine lung. J. Clin. Pathol., 2002, 55 (5), 332-9.
78. Bleasby, K.; Castle, J. C.; Roberts, C. J.; Cheng, C.; Bailey, W. J.; Sina, J. F.; Kulkarni, A. V.; Hafey, M. J.; Evers, R.; Johnson, J. M.; Ulrich, R. G.; Slatter, J. G. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica, 2006, 36 (10-11), 963-88.
79. van der Deen, M.; de Vries, E. G.; Timens, W.; Scheper, R. J.; Timmer-Bosscha, H.; Postma, D. S. ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir. Res., 2005, 6, 59.
80. Paturi, D. K.; Kwatra, D.; Ananthula, H. K.; Pal, D.; Mitra, A. K. Identification and functional characterization of breast cancer resistance protein in human bronchial epithelial cells (Calu-3). Int. J. Pharm., 2010, 384 (1-2), 32-8.
81. Castell, J. V.; Donato, M. T.; Gomez-Lechon, M. J. Metabolism and bioactivation of toxicants in the lung. The in vitro cellular approach. Exp. Toxicol. Pathol., 2005, 57 Suppl 1, 189-204.
82. Nichols, W. K.; Mehta, R.; Skordos, K.; Mace, K.; Pfeifer, A. M.; Carr, B. A.; Minko, T.; Burchiel, S. W.; Yost, G. S. 3-methylindole-induced toxicity to human bronchial epithelial cell lines. Toxicol. Sci., 2003, 71 (2), 229-36.
83. Hukkanen, J.; Lassila, A.; Paivarinta, K.; Valanne, S.; Sarpo, S.; Hakkola, J.; Pelkonen, O.; Raunio, H. Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line. Am. J. Respir. Cell. Mol. Biol., 2000, 22 (3), 360-6.
84. Bo Olsson, E. B., Lars Borgström, Staffan Edsbäcker, Stefan and Eirefelt, K. E., Lena Gustavsson, and Tove Hegelund-Myrbäck, Pulmonary Drug Metabolism, Clearance, and Absorption. In Controlled pulmonary drug delivery, Huhg D.C. Smyth, A. J. H., Ed. Springer: New York, 2011; pp 2-50.
85. Jin, H.; Li, L.; Zhong, D.; Liu, J.; Chen, X.; Zheng, J. Pulmonary toxicity and metabolic activation of tetrandrine in CD-1 mice. Chem. Res. Toxicol., 2011, 24 (12), 2142-52.
86. Nakatomi, K.; Yoshikawa, M.; Oka, M.; Ikegami, Y.; Hayasaka, S.; Sano, K.; Shiozawa, K.; Kawabata, S.; Soda, H.; Ishikawa, T.; Tanabe, S.; Kohno, S. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem. Biophys. Res. Commun., 2001, 288 (4), 827-32.
87. Rivory, L. P.; Bowles, M. R.; Robert, J.; Pond, S. M. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem. Pharmacol., 1996, 52 (7), 1103-11.
88. Kawabata, S.; Oka, M.; Shiozawa, K.; Tsukamoto, K.; Nakatomi, K.; Soda, H.; Fukuda, M.; Ikegami, Y.; Sugahara, K.; Yamada, Y.; Kamihira, S.; Doyle, L. A.; Ross, D. D.; Kohno, S. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem. Biophys. Res. Commun., 2001, 280 (5), 1216-23.
89. Takahashi, H.; Maruo, Y.; Mori, A.; Iwai, M.; Sato, H.; Takeuchi, Y. Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase (UGT1A9). Basic Clin. Pharmacol. Toxicol., 2008, 103 (2), 131-6.
90. Bosquillon, C. Drug transporters in the lung-do they play a role in the biopharmaceutics of inhaled drugs? J. Pharm. Sci., 2010, 99 (5), 2240-55.
91. Agarwal, S.; Elmquist, W. F. Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining soraf-enib efflux clearance. Mol. Pharm., 2012, 9 (3), 678-84.
92. Kallen, C. B. Steroid hormone synthesis in pregnancy. Obstet. Gynecol. Clin. North Am., 2004, 31 (4), 795-816, x.
93. Meyer zu Schwabedissen, H. E.; Grube, M.; Dreisbach, A.; Jedlitschky, G.; Meissner, K.; Linnemann, K.; Fusch, C.; Ritter, C. A.; Volker, U.; Kroemer, H. K. Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP). Drug Metab. Dispos., 2006, 34 (4), 524-33.
94. Grube, M.; Reuther, S.; Meyer Zu Schwabedissen, H.; Kock, K.; Draber, K.; Ritter, C. A.; Fusch, C.; Jedlitschky, G.; Kroemer, H. K. Organic anion transporting polypeptide 2B1 and breast cancer resistance protein interact in the transepithelial transport of steroid sulfates in human placenta. Drug Metab. Dispos., 2007, 35 (1), 30-5.
95. Vaidya, S. S.; Walsh, S. W.; Gerk, P. M. Formation and efflux of ATP-binding cassette transporter substrate 2, 4-dinitrophenyl-S-glutathione from cultured human term placental villous tissue fragments. Mol. Pharm., 2009, 6 (6), 1689-702.
96. van Waterschoot, R. A.; ter Heine, R.; Wagenaar, E.; van der Kruijssen, C. M.; Rooswinkel, R. W.; Huitema, A. D.; Beijnen, J. H.; Schinkel, A. H. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br. J. Pharmacol., 2010, 160 (5), 1224-33.
97. Wu, B.; Jiang, W.; Yin, T.; Gao, S.; Hu, M. A New Strategy to Rapidly Evaluate Kinetics of Glucuronide Efflux by Breast Cancer Resistance Protein (BCRP/ABCG2). Pharm. Res., 2012, 29 (11), 3199-208.
98. Hernandez, J. S.; Watson, R. W.; Wood, T. C.; Weinshilboum, R. M. Sulfation of estrone and 17 beta-estradiol in human liver. Catalysis by thermostable phenol sulfotransferase and by dehydroepiandrosterone sulfotransferase. Drug Metab. Dispos., 1992, 20 (3), 413-22.
99. Raftogianis, R.; Creveling, C.; Weinshilboum, R.; Weisz, J. Estrogen metabolism by conjugation. J. Natl. Cancer Inst. Monogr., 2000, (27), 113-24.
100. Imai, Y.; Asada, S.; Tsukahara, S.; Ishikawa, E.; Tsuruo, T.; Sugimoto, Y. Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol. Pharmacol., 2003, 64 (3), 610-8.
101. Janvilisri, T.; Shahi, S.; Venter, H.; Balakrishnan, L.; van Veen, H. W. Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem. J., 2005, 385 (Pt 2), 419-26.
102. Mesia-Vela, S.; Kauffman, F. C. Inhibition of rat liver sulfotransferases SULT1A1 and SULT2A1 and glucuronosyltransferase by dietary flavonoids. Xenobiotica, 2003, 33 (12), 1211-20.
103. Han, Y. H.; Busler, D.; Hong, Y.; Tian, Y.; Chen, C.; Rodrigues, A. D. Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human liver drug transporters. Drug Metab. Dispos., 2010, 38 (7), 1072-82.
104. Rogers, S. M.; Back, D. J.; Orme, M. L. Intestinal metabolism of ethinyloestradiol and paracetamol in vitro: studies using Ussing chambers. Br. J. Clin. Pharmacol., 1987, 23 (6), 727-34.
105. Han, Y. H.; Busler, D.; Hong, Y.; Tian, Y.; Chen, C. and Rodrigues, A. D. Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human kidney drug transporters. Drug Metab. Dispos., 2010, 38 (7), 1064-71.
106. Zamek-Gliszczynski, M. J.; Day, J. S.; Hillgren, K. M.; Phillips, D. L. Efflux transport is an important determinant of ethinylestradiol glucuronide and ethinylestradiol sulfate pharmacokinetics. Drug Metab. Dispos., 2011, 39 (10), 1794-800.
107. Hessel, S.; Lampen, A.; Seidel, A. Polycyclic aromatic hydrocarbons in food-efflux of the conjugated biomarker 1-hydroxypyrene is mediated by Breast Cancer Resistance Protein (ABCG2) in human intestinal Caco-2 cells. Food Chem. Toxicol., 2013, 62, 797-804.
108. Suzuki, H.; Morris, J. S.; Li, Y.; Doll, M. A.; Hein, D. W.; Liu, J.; Jiao, L.; Hassan, M. M.; Day, R. S.; Bondy, M. L.; Abbruzzese, J. L.; Li, D. Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer. Carcinogenesis, 2008, 29 (6), 1184-91.
109. Zhang, L.; Huang, M.; Blair, I. A.; Penning, T. M. Detoxication of benzo[a]pyrene-7, 8-dione by sulfotransferases (SULTs) in human lung cells. J. Biol. Chem., 2012, 287 (35), 29909-20.
110. Cook, I.; Wang, T.; Falany, C. N. and Leyh, T. S. A nucleotidegated molecular pore selects sulfotransferase substrates. Biochemistry, 2012, 51 (28), 5674-83.
111. Lu, L. Y.; Hsieh, Y. C.; Liu, M. Y.; Lin, Y. H.; Chen, C. J.; Yang, Y. S. Identification and characterization of two amino acids critical for the substrate inhibition of human dehydroepiandrosterone sulfotransferase (SULT2A1). Mol. Pharmacol., 2008, 73 (3), 660-8.
112. Chen, G.; Rabjohn, P. A.; York, J. L.; Wooldridge, C.; Zhang, D.; Falany, C. N.; Radominska-Pandya, A. Carboxyl residues in the active site of human phenol sulfotransferase (SULT1A1). Biochemistry, 2000, 39 (51), 16000-7.
113. Adachi, Y.; Suzuki, H.; Schinkel, A. H.; Sugiyama, Y. Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen. Mol. Pharmacol., 2005, 67 (3), 923-8.
114. Zamek-Gliszczynski, M. J.; Hoffmaster, K. A.; Humphreys, J. E.; Tian, X.; Nezasa, K.; Brouwer, K. L. Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat. J. Pharmacol. Exp. Ther., 2006, 319 (1), 459-67.
115. Brand, W.; Boersma, M. G.; Bik, H.; Hoek-van den Hil, E. F.; Vervoort, J.; Barron, D.; Meinl, W.; Glatt, H.; Williamson, G.; van Bladeren, P. J. and Rietjens, I. M. Phase II metabolism of hesperetin by individual UDP-glucuronosyltransferases and sulfotransferases and rat and human tissue samples. Drug Metab. Dispos., 2010, 38 (4), 617-25.
116. Brand, W.; van der Wel, P. A.; Rein, M. J.; Barron, D.; Williamson, G.; van Bladeren, P. J.; Rietjens, I. M. Metabolism and transport of the citrus flavonoid hesperetin in Caco-2 cell monolayers. Drug Metab. Dispos., 2008, 36 (9), 1794-802.
117. Murias, M.; Miksits, M.; Aust, S.; Spatzenegger, M.; Thalhammer, T.; Szekeres, T.; Jaeger, W. Metabolism of resveratrol in breast cancer cell lines: impact of sulfotransferase 1A1 expression on cell growth inhibition. Cancer Lett., 2008, 261 (2), 172-82.
118. Miksits, M.; Maier-Salamon, A.; Aust, S.; Thalhammer, T.; Reznicek, G.; Kunert, O.; Haslinger, E.; Szekeres, T.; Jaeger, W. Sulfation of resveratrol in human liver: evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1. Xenobiotica, 2005, 35 (12), 1101-19.
119. Doerge, D. R.; Chang, H. C.; Churchwell, M. I.; Holder, C. L. Analysis of soy isoflavone conjugation in vitro and in human blood using liquid chromatography-mass spectrometry. Drug Metab. Dispos., 2000, 28 (3), 298-307.
120. Meng, S.; Wu, B.; Singh, R.; Yin, T.; Morrow, J. K.; Zhang, S.; Hu, M. SULT1A3-mediated regiospecific 7-O-sulfation of flavonoids in Caco-2 cells can be explained by the relevant molecular docking studies. Mol. Pharm., 2012, 9 (4), 862-73.
121. Nakano, H.; Ogura, K.; Takahashi, E.; Harada, T.; Nishiyama, T.; Muro, K.; Hiratsuka, A.; Kadota, S.; Watabe, T. Regioselective monosulfation and disulfation of the phytoestrogens daidzein and genistein by human liver sulfotransferases. Drug Metab. Pharmacokinet., 2004, 19 (3), 216-26.
122. An, G.; Morris, M. E. The sulfated conjugate of biochanin A is a substrate of breast cancer resistant protein (ABCG2). Biopharm. Drug Dispos., 2011, 32 (8), 446-57.
123. Gulcan, H. O.; Liu, Y.; Duffel, M. W. Pentachlorophenol and other chlorinated phenols are substrates for human hydroxysteroid sul-fotransferase hSULT2A1. Chem. Res. Toxicol., 2008, 21 (8), 1503-8.
124. Ng, K. H.; Lim, B. G.; Wong, K. P. Sulfate conjugating and transport functions of MDCK distal tubular cells. Kidney Int., 2003, 63 (3), 976-86.
125. Harris, R. M.; Waring, R. H. Sulfotransferase inhibition: potential impact of diet and environmental chemicals on steroid metabolism and drug detoxification. Curr. Drug Metab., 2008, 9 (4), 269-75.
126. Runge-Morris, M.; Rose, K.; Falany, C. N.; Kocarek, T. A. Differential regulation of individual sulfotransferase isoforms by phenobarbital in male rat liver. Drug Metab. Dispos., 1998, 26 (8), 795-801.
127. Dooley, T. P.; Haldeman-Cahill, R.; Joiner, J.; Wilborn, T. W. Expression profiling of human sulfotransferase and sulfatase gene superfamilies in epithelial tissues and cultured cells. Biochem. Biophys. Res. Commun., 2000, 277 (1), 236-45.
128. Huang, T.; Fang, Z. Z.; Yang, L. Strong inhibitory effect of medroxyprogesterone acetate (MPA) on UDP-glucuronosyltransferase (UGT) 2B7 might induce drug-drug interactions. Pharmazie, 2010, 65 (12), 919-21.
129. Fu, J. F.; Ren, Q. Y.; Zhang, N. Y.; Gao, B.; Tu, Y. Y.; Fu, G. Q.; Li, D. H.; Zhang, Y. S. Inhibition potential of glimepiride (gli) towards important UDP-glucuronosyltransferase (UGT) isoforms in human liver. Pharmazie, 2012, 67 (8), 715-7.
130. Lewis, B. C.; Mackenzie, P. I.; Elliot, D. J.; Burchell, B.; Bhasker, C. R.; Miners, J. O. Amino terminal domains of human UDP-glucuronosyltransferases (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation. Biochem. Pharmacol., 2007, 73 (9), 1463-73.
131. Brand, W.; Oosterhuis, B.; Krajcsi, P.; Barron, D.; Dionisi, F.; van Bladeren, P. J.; Rietjens, I. M.; Williamson, G. Interaction of hesperetin glucuronide conjugates with human BCRP, MRP2 and MRP3 as detected in membrane vesicles of overexpressing baculovirus-infected Sf9 cells. Biopharm. Drug Dispos., 2011, 32 (9), 530-5.
132. Miura, M.; Kagaya, H.; Satoh, S.; Inoue, K.; Saito, M.; Habuchi, T.; Suzuki, T. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther. Drug Monit., 2008, 30 (5), 559-64.
133. Zhang, L.; Lin, G.; Zuo, Z. Involvement of UDP-glucuronosyltransferases in the extensive liver and intestinal firstpass metabolism of flavonoid baicalein. Pharm. Res., 2007, 24 (1), 81-9.
134. Green, M. D.; King, C. D.; Mojarrabi, B.; Mackenzie, P. I.; Tephly, T. R. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab. Dispos., 1998, 26 (6), 507-12.
135. Court, M. H.; Duan, S. X.; Guillemette, C.; Journault, K.; Krishnaswamy, S.; Von Moltke, L. L.; Greenblatt, D. J. Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab. Dispos., 2002, 30 (11), 1257-65.
136. Wu, B.; Morrow, J. K.; Singh, R.; Zhang, S.; Hu, M. Three-dimensional quantitative structure-activity relationship studies on UGT1A9-mediated 3-O-glucuronidation of natural flavonols using a pharmacophore-based comparative molecular field analysis model. J. Pharmacol. Exp. Ther., 336 (2), 403-13.
137. Nikolic, D.; Li, Y.; Chadwick, L. R.; van Breemen, R. B. In vitro studies of intestinal permeability and hepatic and intestinal metabolism of 8-prenylnaringenin, a potent phytoestrogen from hops (Humulus lupulus L.). Pharm Res., 2006, 23 (5), 864-72.
138. Xu, H.; Kulkarni, K. H.; Singh, R.; Yang, Z.; Wang, S. W.; Tam, V. H.; Hu, M. Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides. Mol. Pharm. 2009, 6 (6), 1703-15.
139. Lancon, A.; Hanet, N.; Jannin, B.; Delmas, D.; Heydel, J. M.; Lizard, G.; Chagnon, M. C.; Artur, Y.; Latruffe, N. Resveratrol in hu-man hepatoma HepG2 cells: metabolism and inducibility of detoxifying enzymes. Drug Metab. Dispos., 2007, 35 (5), 699-703.
140. Lagas, J. S.; Sparidans, R. W.; Wagenaar, E.; Beijnen, J. H.; Schinkel, A. H. Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters. Mol. Pharmacol., 2010, 77 (4), 687-94.
141. Zhang, L.; Lin, G.; Kovacs, B.; Jani, M.; Krajcsi, P.; Zuo, Z. Mechanistic study on the intestinal absorption and disposition of baicalein. Eur. J. Pharm. Sci., 2007, 31 (3-4), 221-31.
142. Zhang, L.; Li, C.; Lin, G.; Krajcsi, P.; Zuo, Z. Hepatic metabolism and disposition of baicalein via the coupling of conjugation enzymes and transporters-in vitro and in vivo evidences. AAPS J., 2011, 13 (3), 378-89.
143. Tang, L.; Singh, R.; Liu, Z.; Hu, M. Structure and concentration changes affect characterization of UGT isoform-specific metabolism of isoflavones. Mol. Pharm. 2009, 6 (5), 1466-82.
144. Pritchett, L. E.; Atherton, K. M.; Mutch, E.; Ford, D. Glucuronidation of the soyabean isoflavones genistein and daidzein by human liver is related to levels of UGT1A1 and UGT1A9 activity and alters isoflavone response in the MCF-7 human breast cancer cell line. J. Nutr. Biochem., 2008, 19 (11), 739-45.
145. Webb, L. J.; Miles, K. K.; Auyeung, D. J.; Kessler, F. K.; Ritter, J. K. Analysis of substrate specificities and tissue expression of rat UDP-glucuronosyltransferases UGT1A7 and UGT1A8. Drug Metab. Dispos., 2005, 33 (1), 77-82.
146. Chen, Y. K.; Chen, S. Q.; Li, X.; Zeng, S. Quantitative regioselectivity of glucuronidation of quercetin by recombinant UDP-glucuronosyltransferases 1A9 and 1A3 using enzymatic kinetic parameters. Xenobiotica, 2005, 35 (10-11), 943-54.
147. Gagne, J. F.; Montminy, V.; Belanger, P.; Journault, K.; Gaucher, G.; Guillemette, C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol. Pharmacol., 2002, 62 (3), 608-17.
148. Vaidya, S. S.; Gerk, P. M. Simultaneous determination of 1-chloro-2, 4-dinitrobenzene, 2, 4-dinitrophenyl-S-glutathione and its metabolites for human placental disposition studies by high-performance liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 859 (1), 94-102.
149. Hatfield, M. J.; Tsurkan, L.; Garrett, M.; Shaver, T. M.; Hyatt, J. L.; Edwards, C. C.; Hicks, L. D.; Potter, P. M. Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11. Biochem. Pharmacol., 2011, 81 (1), 24-31.
150. Shingyoji, M.; Takiguchi, Y.; Watanabe-Uruma, R.; AsakaAmano, Y.; Matsubara, H.; Kurosu, K.; Kasahara, Y.; Tanabe, N.; Tatsumi, K.; Kuriyama, T. In vitro conversion of irinotecan to SN-38 in human plasma. Cancer Sci., 2004, 95 (6), 537-40.
151. Xu, G.; Zhang, W.; Ma, M. K.; McLeod, H. L. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin. Cancer Res., 2002, 8 (8), 2605-11.